Clinical Trial Update: Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy [Phase 2]

View source ↗

Summary

The Phase 2 trial of luminespib (AUY922) in metastatic pancreatic cancer resistant to first-line chemotherapy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• luminespib (luminespib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Adenocarcinoma of the Pancreas, Metastatic Disease | Phase 2 | Status: TERMINATED